486460-32-6 | (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$19.00	$13.00
5g	98%	in stock	$23.00	$16.00
25g	98%	in stock	$78.00	$54.00

Description

• Catalog Number: AI51015
• Chemical Name: (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
• CAS Number: 486460-32-6
• Molecular Formula: C16H15F6N5O
• Molecular Weight: 407.3136
• MDL Number: MFCD09838015
• SMILES: N[C@H](Cc1cc(F)c(cc1F)F)CC(=O)N1CCn2c(C1)nnc2C(F)(F)F

Computed Properties

• Complexity: 566
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 0.7

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

  Journal of medicinal chemistry 20140424

• High fat diet and GLP-1 drugs induce pancreatic injury in mice.

  Toxicology and applied pharmacology 20140415

• Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

  Journal of molecular modeling 20140401

• Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

  ACS medicinal chemistry letters 20130808

• Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.

  Chemico-biological interactions 20130425

• A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

  European journal of pharmacology 20121205

• Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201

• Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201

• Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

  Regulatory peptides 20121110

• Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

  Journal of clinical pharmacology 20121001

• Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20121001

• Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

  Diabetes, obesity & metabolism 20121001

• No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

  Diabetes, obesity & metabolism 20121001

• Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

  Diabetes research and clinical practice 20121001

• Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

  Diabetes care 20121001

• Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

  Diabetes technology & therapeutics 20121001

• Recent advances in incretin-based therapies.

  Clinical endocrinology 20121001

• Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

  Diabetes & metabolism 20121001

• Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.

  Bioorganic & medicinal chemistry 20121001

• Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.

  Journal of clinical medicine research 20121001

• Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.

  Journal of cardiac failure 20121001

• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.

  Advances in therapy 20121001

• Linagliptin as add-on therapy for type 2 diabetes - an overview.

  Drugs of today (Barcelona, Spain : 1998) 20121001

• Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

  Diabetes, obesity & metabolism 20120901

• Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.

  Diabetes, obesity & metabolism 20120901

• The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

  Journal of diabetes 20120901

• Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers.

  Diabetologia 20120901

• Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease.

  Naunyn-Schmiedeberg's archives of pharmacology 20120901

• Sitagliptin exerts an antinflammatory action.

  The Journal of clinical endocrinology and metabolism 20120901

• Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

  Hypertension (Dallas, Tex. : 1979) 20120901

• Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.

  Hypertension (Dallas, Tex. : 1979) 20120901

• [Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].

  MMW Fortschritte der Medizin 20120823

• Exenatide extended-release: a review of its use in type 2 diabetes mellitus.

  Drugs 20120820

• Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

  Clinical endocrinology 20120801

• Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.

  The Journal of dermatology 20120801

• Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

  Diabetes, obesity & metabolism 20120801

• GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

  Current clinical pharmacology 20120801

• Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

  Diabetes, obesity & metabolism 20120801

• Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

  Diabetologia 20120801

• Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20120801

• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  Clinical pharmacokinetics 20120801

• Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.

  Current medical research and opinion 20120801

• The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.

  Alimentary pharmacology & therapeutics 20120801

• Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

  Current medical research and opinion 20120801

• Mechanism of action of DPP-4 inhibitors--new insights.

  The Journal of clinical endocrinology and metabolism 20120801

• Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.

  Journal of clinical medicine research 20120801

• Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

  Diabetes, obesity & metabolism 20120701

• Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.

  Diabetes, obesity & metabolism 20120701

• The pancreatic beta cell surface proteome.

  Diabetologia 20120701

• The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

  Diabetes technology & therapeutics 20120701

• Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.

  Current medical research and opinion 20120701

• The incretin hormones: from scientific discovery to practical therapeutics.

  Diabetologia 20120701

• Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

  Current medical research and opinion 20120701

• Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.

  Journal of clinical hypertension (Greenwich, Conn.) 20120701

• [Liraglutide: new results in the treatment of type 2 diabetes mellitus].

  Drugs of today (Barcelona, Spain : 1998) 20120701

• Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

  Lancet (London, England) 20120616

• Choosing a blood-glucose-lowering agent after metformin.

  Lancet (London, England) 20120616

• Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120615

• Sitagliptin counteracts seasonal fluctuation of glycemic control.

  World journal of diabetes 20120615

• Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.

  Journal of medicinal chemistry 20120614

• [Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].

  Zhonghua yi xue za zhi 20120612

• Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

  Acta diabetologica 20120601

• Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

  Diabetes, obesity & metabolism 20120601

• Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

  Diabetes care 20120601

• Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

  Expert opinion on drug metabolism & toxicology 20120601

• Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.

  Acta gastro-enterologica Belgica 20120601

• Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

  Bioorganic & medicinal chemistry letters 20120515

• Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.

  Diabetic medicine : a journal of the British Diabetic Association 20120501

• Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20120501

• Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.

  Diabetes, obesity & metabolism 20120501

• Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.

  European journal of clinical pharmacology 20120501

• Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.

  Diabetes/metabolism research and reviews 20120501

• An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

  Current diabetes reviews 20120501

• High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501

• Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.

  International journal of clinical practice 20120501

• Prediction of drug-target interactions and drug repositioning via network-based inference.

  PLoS computational biology 20120501

• Immunotherapies in diabetes mellitus type 1.

  The Medical clinics of North America 20120501

• Association between sitagliptin adherence and self-monitoring of blood glucose.

  Journal of diabetes science and technology 20120501

• Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.

  Chinese medical journal 20120501

• The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.

  American journal of physiology. Gastrointestinal and liver physiology 20120415

• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  Diabetes & metabolism 20120401

• Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.

  Neurobiology of disease 20120401

• Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

  Diabetes technology & therapeutics 20120401

• The design of the liraglutide clinical trial programme.

  Diabetes, obesity & metabolism 20120401

• Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

  Diabetes, obesity & metabolism 20120401

• Liraglutide: from clinical trials to clinical practice.

  Diabetes, obesity & metabolism 20120401

• Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

  Diabetic medicine : a journal of the British Diabetic Association 20120301

• Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20120301

• Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.

  Minerva endocrinologica 20120301

• Pleiotropic effects of incretins.

  Indian journal of endocrinology and metabolism 20120301

• Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.

  The Journal of the Association of Physicians of India 20120301

• Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.

  Oncogene 20120223

• The importance of green chemistry in process research and development.

  Chemical Society reviews 20120221

• Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).

  Dermatology online journal 20120215

• Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20120201

• Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.

  Cancer chemotherapy and pharmacology 20120201

• Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.

  Diabetes research and clinical practice 20120201

• Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

  Experimental hematology 20120201

• Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

  Endocrinology 20120201

• Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

  Diabetes care 20120201

• Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.

  The Australasian journal of dermatology 20120201

• Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

  Drugs 20120122

• A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

  Journal of the American College of Cardiology 20120117

• Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.

  Journal of the American College of Cardiology 20120117

• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

  Diabetes, obesity & metabolism 20120101

• Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

  Journal of nephrology 20120101

• Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.

  European journal of heart failure 20120101

• Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20120101

• The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

  Diabetes research and clinical practice 20120101

• Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.

  Dermatology (Basel, Switzerland) 20120101

• Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Diabetes: impaired damage control.

  Diabetologia 20120101

• Why do metabolites circulate?

  Xenobiotica; the fate of foreign compounds in biological systems 20120101

• Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells.

  Acta pharmacologica Sinica 20120101

• A review of gliptins in 2011.

  Expert opinion on pharmacotherapy 20120101

• Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

  Translational research : the journal of laboratory and clinical medicine 20120101

• Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.

  Hepato-gastroenterology 20120101

• Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.

  Endocrine journal 20120101

• Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients.

  Basic research in cardiology 20120101

• [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101

• DPP-4 inhibitors and lipids: systematic review and meta-analysis.

  Advances in therapy 20120101

• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

  Cardiovascular diabetology 20120101

• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

  BMJ (Clinical research ed.) 20120101

• Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

  Cardiovascular diabetology 20120101

• A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.

  Pharmacoepidemiology and drug safety 20120101

• Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.

  Endocrine journal 20120101

• Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation.

  Skeletal muscle 20120101

• Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

  Journal of medical economics 20120101

• Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia.

  Journal of neuroinflammation 20120101

• Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

  Gut and liver 20120101

• Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.

  PloS one 20120101

• Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.

  Diabetology & metabolic syndrome 20120101

• Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method.

  Scientia pharmaceutica 20120101

• Perioperative glucose control in neurosurgical patients.

  Anesthesiology research and practice 20120101

• Reversible mitral and aortic regurgitation due to pioglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Prioritisation of clinical research by the example of type 2 diabetes: a caregiver-survey on perceived relevance and need for evidence.

  PloS one 20120101

• The influence of incretin mimetics on cardiovascular risk factors in diabetes.

  ISRN endocrinology 20120101

• Prescribing gliptins: Enthusiasm should be coupled with caution.

  Indian journal of endocrinology and metabolism 20120101

• Strategies to reverse endothelial progenitor cell dysfunction in diabetes.

  Experimental diabetes research 20120101

• Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

  BMC pharmacology 20120101

• Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report.

  Case reports in medicine 20120101

• Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.

  PloS one 20120101

• Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes.

  Journal of biomedical semantics 20120101

• It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications.

  Experimental diabetes research 20120101

• Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.

  CANNT journal = Journal ACITN 20120101

• Uncovering undetected hypoglycemic events.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.

  Vascular health and risk management 20120101

• Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

  Experimental diabetes research 20120101

• A simple matter of life and death-the trials of postnatal Beta-cell mass regulation.

  International journal of endocrinology 20120101

• Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

  ISRN endocrinology 20120101

• A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy.

  Endocrine research 20120101

• Red carpeting the newer antidiabetics.

  Journal of pharmacology & pharmacotherapeutics 20120101

• The management of type 2 diabetic patients with hypoglycaemic agents.

  ISRN endocrinology 20120101

• Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Hypoglycemia in type 2 diabetes: current controversies and changing practices.

  Frontiers in endocrinology 20120101

• TGR5 potentiates GLP-1 secretion in response to anionic exchange resins.

  Scientific reports 20120101

• Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

  Experimental diabetes research 20120101

• Pain from a Bullet Lingers on: An Uncommon Case of Lead Toxicity.

  Case reports in gastroenterology 20120101

• Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.

  Current medicinal chemistry 20120101

• Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

  Journal of medical economics 20120101

• Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.

  Internal medicine (Tokyo, Japan) 20120101

• Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

  Cardiovascular diabetology 20120101

• Simultaneous determination of sitagliptin and metformin in pharmaceutical preparations by capillary zone electrophoresis and its application to human plasma analysis.

  Analytical chemistry insights 20120101

• The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

  TheScientificWorldJournal 20120101

• Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.

  Pharmacology 20120101

• Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.

  Swiss medical weekly 20120101

• Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.

  Scientia pharmaceutica 20120101

• Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study.

  International journal of endocrinology 20120101

• The effects of simvastatin on the pharmacokinectics of sitagliptin.

  Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 20120101

• Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

  BMJ open 20120101

• Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.

  Journal of nutrition and metabolism 20120101

• Impact of diabetes on postinfarction heart failure and left ventricular remodeling.

  Current heart failure reports 20111201

• Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

  Journal of molecular and cellular cardiology 20111201

• Optimization of cardiac metabolism in heart failure.

  Current pharmaceutical design 20111201

• Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

  Transplantation 20111127

• [Incretin-based therapy for treating patients with type 2 diabetes].

  Orvosi hetilap 20111127

• Sitagliptin and simvastatin (juvisync).

  The Medical letter on drugs and therapeutics 20111114

• Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

  Diabetes, obesity & metabolism 20111101

• Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

  Diabetes technology & therapeutics 20111101

• Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.

  Progress in biophysics and molecular biology 20111101

• Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.

  Diabetes research and clinical practice 20111101

• Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

  Xenobiotica; the fate of foreign compounds in biological systems 20111101

• The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.

  Basic research in cardiology 20111101

• The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

  International journal of clinical practice 20111101

• Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

  Prescrire international 20111101

• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  Clinical therapeutics 20111101

• Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

  Current medical research and opinion 20111101

• Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.

  BMB reports 20111101

• Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

  Current drug safety 20111101

• [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].

  Drugs of today (Barcelona, Spain : 1998) 20111101

• Glucagon-like peptide analogues for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20111005

• Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.

  Diabetes technology & therapeutics 20111001

• Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

  Diabetic medicine : a journal of the British Diabetic Association 20111001

• The efficacy and safety of liraglutide.

  International journal of clinical pharmacy 20111001

• Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy.

  Electrophoresis 20111001

• Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.

  Diabetes & metabolism journal 20111001

• 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.

  Bioorganic & medicinal chemistry 20110915

• [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

  Orvosi hetilap 20110911

• DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells.

  Biochemical and biophysical research communications 20110909

• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

  Journal of clinical pharmacology 20110901

• Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

  Expert opinion on pharmacotherapy 20110901

• A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

  Diabetes, obesity & metabolism 20110901

• The metabolic syndrome influences the response to incretin-based therapies.

  Acta diabetologica 20110901

• Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

  International journal of clinical practice 20110901

• Next-generation GLP-1 therapy: an introduction to liraglutide.

  Postgraduate medicine 20110901

• Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.

  Recent patents on endocrine, metabolic & immune drug discovery 20110901

• Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

  Current diabetes reviews 20110901

• Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110901

• Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Emerging role of insulin with incretin therapies for management of type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

  Journal of medicinal chemistry 20110825

• Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine.

  Talanta 20110815

• Merging the best of two worlds: artificial metalloenzymes for enantioselective catalysis.

  Chemical communications (Cambridge, England) 20110814

• Inhibition of anaphylaxis like reaction and mast cell activation by Sitagliptin.

  International immunopharmacology 20110801

• DPP-IV inhibitor may affect spermatogenesis.

  Diabetes research and clinical practice 20110801

• Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

  Endocrinology 20110801

• Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.

  Surgery 20110801

• Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.

  Pancreas 20110801

• Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20110801

• Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.

  Diabetes & metabolism journal 20110801

• Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.

  Expert opinion on drug discovery 20110801

• Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

  Drugs 20110730

• Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.

  The Journal of biological chemistry 20110722

• Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.

  Talanta 20110715

• Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

  Diabetes, obesity & metabolism 20110701

• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  Gastroenterology 20110701

• The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20110701

• Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.

  Diabetes research and clinical practice 20110701

• Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.

  Diabetes research and clinical practice 20110701

• Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

  Diabetes technology & therapeutics 20110701

• Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors.

  Nature chemical biology 20110701

• Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.

  Pancreas 20110701

• Sitagliptin: a review.

  Expert opinion on pharmacotherapy 20110701

• GLP-1-based therapies: the dilemma of uncertainty.

  Gastroenterology 20110701

• Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

  The Annals of pharmacotherapy 20110701

• Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

  British journal of hospital medicine (London, England : 2005) 20110701

• Health economic evaluation of dipeptidyl peptidase-4 inhibitors.

  Indian journal of endocrinology and metabolism 20110701

• DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

  Diabetic medicine : a journal of the British Diabetic Association 20110601

• Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.

  Hepatology research : the official journal of the Japan Society of Hepatology 20110601

• Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20110601

• Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

  Diabetes care 20110601

• Use of metformin in the setting of mild-to-moderate renal insufficiency.

  Diabetes care 20110601

• Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.

  Journal of the American Geriatrics Society 20110601

• Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report.

  Transplantation proceedings 20110601

• Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration.

  Diabetes & metabolism journal 20110601

• Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65).

  Diabetes & metabolism journal 20110601

• Response: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65).

  Diabetes & metabolism journal 20110601

• Place in therapy for liraglutide and saxagliptin for type 2 diabetes.

  Southern medical journal 20110601

• [Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry].

  Se pu = Chinese journal of chromatography 20110601

• An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

  Contemporary clinical trials 20110501

• Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

  Diabetes research and clinical practice 20110501

• Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

  Current medical research and opinion 20110501

• Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment.

  Postgraduate medicine 20110501

• [Incretin enhancer: sitagliptin].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• Liraglutide for the treatment of type 2 diabetes.

  Health technology assessment (Winchester, England) 20110501

• Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20110501

• Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

  Clinical therapeutics 20110501

• Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501

• Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501

• Journal withdraws article after complaints from drug manufacturers.

  BMJ (Clinical research ed.) 20110411

• Status of protein engineering for biocatalysts: how to design an industrially useful biocatalyst.

  Current opinion in chemical biology 20110401

• Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

  Diabetes, obesity & metabolism 20110401

• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110401

• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110401

• Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.

  Analytical and bioanalytical chemistry 20110401

• Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

  Diabetes 20110401

• One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.

  International journal of clinical practice 20110401

• [Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].

  Wiener klinische Wochenschrift 20110401

• Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

  Diabetes & metabolism journal 20110401

• Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.

  Diabetes & metabolism journal 20110401

• Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.

  Diabetes & metabolism journal 20110401

• Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice.

  European journal of pharmacology 20110325

• Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors.

  Bioorganic & medicinal chemistry letters 20110315

• Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry letters 20110315

• Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

  Journal of hypertension 20110301

• Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

  Biological chemistry 20110301

• Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

  Biological chemistry 20110301

• Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

  Diabetes, obesity & metabolism 20110301

• Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

  British journal of clinical pharmacology 20110301

• Sitagliptin and metformin--novel combination therapy.

  Expert opinion on pharmacotherapy 20110301

• Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20110301

• Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

  Diabetic medicine : a journal of the British Diabetic Association 20110301

• Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.

  Experimental biology and medicine (Maywood, N.J.) 20110301

• A diabetes drug, sitagliptin, also has a potential to prevent diabetes.

  Experimental biology and medicine (Maywood, N.J.) 20110301

• Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110301

• Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.

  Angewandte Chemie (International ed. in English) 20110225

• Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

  Drugs 20110212

• Severe leucopenia associated with Sitagliptin use.

  Diabetes research and clinical practice 20110201

• Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

  American journal of physiology. Endocrinology and metabolism 20110201

• Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

  Endocrinology 20110201

• Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

  Diabetes, obesity & metabolism 20110201

• Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

  International journal of clinical practice 20110201

• Type 2 diabetes: uses of thiazolidinediones and insulin.

  Diabetes care 20110201

• Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

  Diabetes care 20110201

• Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.

  Diabetes care 20110201

• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

  The Tohoku journal of experimental medicine 20110201

• Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

  The Journal of the American Osteopathic Association 20110201

• Alogliptin for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20110201

• Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

  Hospital practice (1995) 20110201

• Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

  Prescrire international 20110201

• Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

  Journal of medicinal chemistry 20110127

• Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.

  Regulatory peptides 20110117

• Advances in the treatment of type 2 diabetes mellitus.

  American journal of therapeutics 20110101

• Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

  Clinical science (London, England : 1979) 20110101

• Weight considerations in pharmacotherapy for type 2 diabetes.

  Journal of obesity 20110101

• Anti-inflammatory nutrition as a pharmacological approach to treat obesity.

  Journal of obesity 20110101

• Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

  Diabetes, obesity & metabolism 20110101

• Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.

  Diabetes technology & therapeutics 20110101

• Sitagliptin reduces albuminuria in patients with type 2 diabetes.

  Endocrine journal 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Rodent models for metabolic syndrome research.

  Journal of biomedicine & biotechnology 20110101

• Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

  Postgraduate medicine 20110101

• Vildagliptin-induced acute pancreatitis.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations' by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).

  Journal of diabetes and its complications 20110101

• Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.

  Cardiology research and practice 20110101

• Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.

  Journal of medical case reports 20110101

• Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

  BMC endocrine disorders 20110101

• A case of drug-induced hepatic injury associated with sitagliptin.

  Internal medicine (Tokyo, Japan) 20110101

• Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.

  Experimental diabetes research 20110101

• Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.

  PloS one 20110101

• Amebic encephalitis.

  Surgical neurology international 20110101

• Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.

  Experimental diabetes research 20110101

• Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report.

  Journal of medical case reports 20110101

• Diabetes and Ramadan: an update on use of glycemic therapies during fasting.

  Annals of Saudi medicine 20110101

• Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.

  Indian journal of endocrinology and metabolism 20110101

• Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.

  Cardiovascular diabetology 20110101

• Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.

  Experimental diabetes research 20110101

• Glucagon-like peptide-1 gene therapy.

  Experimental diabetes research 20110101

• From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

  Experimental diabetes research 20110101

• Electroacupuncture-induced cholinergic nerve activation enhances the hypoglycemic effect of exogenous insulin in a rat model of streptozotocin-induced diabetes.

  Experimental diabetes research 20110101

• New onset diabetes after transplantation (NODAT): an overview.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

  The open cardiovascular medicine journal 20110101

• Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.

  Journal of nutrition and metabolism 20110101

• Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation.

  Diabetology & metabolic syndrome 20110101

• Reply to the 'Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'', by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).

  Journal of diabetes and its complications 20110101

• Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

  Clinical drug investigation 20110101

• Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

  Experimental diabetes research 20110101

• Effects of the Soluble Fiber Complex PolyGlycopleX on Glucose Homeostasis and Body Weight in Young Zucker Diabetic Rats.

  Frontiers in pharmacology 20110101

• [Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study 'SUGAR'].

  Revue medicale de Liege 20110101

• Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

  Cardiovascular diabetology 20110101

• Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

  The open medicinal chemistry journal 20110101

• Valorising and creating access to innovative medicines in the European union.

  Frontiers in pharmacology 20110101

• Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.

  Core evidence 20110101

• Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.

  Hepato-gastroenterology 20110101

• Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

  Journal of pharmacology & pharmacotherapeutics 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Choosing a gliptin.

  Indian journal of endocrinology and metabolism 20110101

• Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

  Open medicine : a peer-reviewed, independent, open-access journal 20110101

• Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

  PloS one 20110101

• Management of diabetes across the course of disease: minimizing obesity-associated complications.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Functional expression and characterization of dipeptidyl peptidase IV from the black-bellied hornet Vespa basalis in Sf21 insect cells.

  Bioscience, biotechnology, and biochemistry 20110101

• Development of a nongenetic mouse model of type 2 diabetes.

  Experimental diabetes research 20110101

• A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.

  Cardiovascular diabetology 20110101

• Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

  Experimental diabetes research 20110101

• Predicting biological functions of compounds based on chemical-chemical interactions.

  PloS one 20110101

• A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20101203

• Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study.

  Diabetes care 20101201

• Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study.

  Diabetes care 20101201

• Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.

  Xenobiotica; the fate of foreign compounds in biological systems 20101201

• Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.

  Mayo Clinic proceedings 20101201

• [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].

  Drugs of today (Barcelona, Spain : 1998) 20101201

• Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.

  Korean diabetes journal 20101201

• Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

• Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis.

  International journal of cardiology 20101119

• Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

  Diabetes care 20101101

• DPP-4 inhibitors: what may be the clinical differentiators?

  Diabetes research and clinical practice 20101101

• Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors.

  European journal of medicinal chemistry 20101101

• Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.

  Current diabetes reviews 20101101

• Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.

  International journal of clinical practice 20101101

• [Medication of the month. Sitagliptin-metformin fixed combination (Janumet)].

  Revue medicale de Liege 20101101

• [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].

  MMW Fortschritte der Medizin 20101007

• SLCO1B1 polymorphism and oral antidiabetic drugs.

  Basic & clinical pharmacology & toxicology 20101001

• Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.

  Hypertension (Dallas, Tex. : 1979) 20101001

• Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

  Hypertension (Dallas, Tex. : 1979) 20101001

• Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

  Expert opinion on drug metabolism & toxicology 20101001

• Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.

  Diabetes research and clinical practice 20101001

• Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

  Diabetes/metabolism research and reviews 20101001

• American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.

  IDrugs : the investigational drugs journal 20101001

• Glycaemic control with liraglutide: the phase 3 trial programme.

  International journal of clinical practice. Supplement 20101001

• Liraglutide: effects beyond glycaemic control in diabetes treatment.

  International journal of clinical practice. Supplement 20101001

• Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.

  Diabetes, obesity & metabolism 20101001

• Sitagliptin-induced hemolysis.

  Indian journal of pharmacology 20101001

• Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

  The American journal of geriatric pharmacotherapy 20101001

• Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.

  Journal of medicinal chemistry 20100923

• Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

  Clinical pharmacokinetics 20100901

• Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go ..

  Diabetes care 20100901

• Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Patient education and self-management.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Introduction.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.

  The Journal of family practice 20100901

• Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor.

  Postgraduate medicine 20100901

• [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].

  Medicina clinica 20100901

• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  Lancet (London, England) 20100807

• Individualised incretin-based treatment for type 2 diabetes.

  Lancet (London, England) 20100807

• The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

  Clinical endocrinology 20100801

• Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20100801

• Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

  Diabetes care 20100801

• The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.

  Diabetes care 20100801

• Managing type 2 diabetes in the primary care setting: beyond glucocentricity.

  The American journal of the medical sciences 20100801

• Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

  Diabetes, obesity & metabolism 20100801

• Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone.

  Evidence-based medicine 20100801

• Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

  Expert opinion on investigational drugs 20100801

• Recommendations for management of diabetes during Ramadan: update 2010.

  Diabetes care 20100801

• Sitagliptin in treatment of diabetes complicated by chronic hepatitis C.

  Hepatobiliary & pancreatic diseases international : HBPD INT 20100801

• Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.

  The American journal of managed care 20100801

• Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.

  Indian journal of pharmacology 20100801

• A medicinal chemist's guide to molecular interactions.

  Journal of medicinal chemistry 20100722

• Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture.

  Science (New York, N.Y.) 20100716

• Biochemistry. Reengineering enzymes.

  Science (New York, N.Y.) 20100716

• Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.

  Archives of internal medicine 20100712

• Induced-fit mechanism for prolyl endopeptidase.

  The Journal of biological chemistry 20100709

• The evolving place of incretin-based therapies in type 2 diabetes.

  Pediatric nephrology (Berlin, Germany) 20100701

• The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.

  Diabetes 20100701

• Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

  Diabetologia 20100701

• Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

  Diabetes care 20100701

• The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

  Diabetes care 20100701

• Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

  Diabetes 20100701

• Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.

  Clinical and experimental pharmacology & physiology 20100701

• Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.

  Current medical research and opinion 20100701

• Diabetes and cancer: a consensus report.

  Diabetes care 20100701

• GIP: an inconsequential incretin or not?

  Diabetes care 20100701

• Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.

  Diabetes, obesity & metabolism 20100701

• Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100701

• Incretin physiology and its role in type 2 diabetes mellitus.

  The Journal of the American Osteopathic Association 20100701

• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100701

• [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

  Orvosi hetilap 20100620

• (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

  Bioorganic & medicinal chemistry letters 20100615

• Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses.

  Cell metabolism 20100609

• Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.

  Clinical science (London, England : 1979) 20100608

• Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20100601

• Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

  International journal of clinical practice 20100601

• Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

  Pharmacotherapy 20100601

• Diabesity: therapeutic options.

  Diabetes, obesity & metabolism 20100601

• The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

  American journal of physiology. Heart and circulatory physiology 20100501

• Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

  Diabetes, obesity & metabolism 20100501

• Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.

  Diabetes, obesity & metabolism 20100501

• Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100501

• Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.

  Postgraduate medicine 20100501

• Choosing among the incretin agents and why it matters.

  The Journal of family practice 20100501

• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  Lancet (London, England) 20100424

• [New hypoglycemic agents in type 2 diabetes].

  La Revue du praticien 20100420

• Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.

  Diabetes care 20100401

• Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

  Diabetes 20100401

• Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Current opinion in investigational drugs (London, England : 2000) 20100401

• Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

  Diabetes, obesity & metabolism 20100401

• Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20100401

• Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA.

  Evidence-based medicine 20100401

• Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

  International journal of clinical practice 20100401

• Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.

  Advances in therapy 20100401

• Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Sitagliptin: too many cases of pancreatitis.

  Prescrire international 20100401

• Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

  Drugs 20100305

• The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.

  Diabetologia 20100301

• Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

  Experimental gerontology 20100301

• Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100301

• DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.

  Circulation. Cardiovascular imaging 20100301

• Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.

  Diabetes research and clinical practice 20100301

• [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

  Pharmazie in unserer Zeit 20100301

• Incretin-based therapies: review of current clinical trial data.

  The American journal of medicine 20100301

• [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

  Medizinische Klinik (Munich, Germany : 1983) 20100301

• New therapeutic options: management strategies to optimize glycemic control.

  The Journal of the American Osteopathic Association 20100301

• The physiologic role of incretin hormones: clinical applications.

  The Journal of the American Osteopathic Association 20100301

• [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].

  Revue medicale de Liege 20100301

• Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial.

  Diabetes care 20100201

• Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.

  ChemMedChem 20100201

• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100201

• Incretin concepts.

  Diabetes care 20100201

• Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

  Diabetes care 20100201

• GLP-1-based therapy for diabetes: what you do not know can hurt you.

  Diabetes care 20100201

• Elevated hepatic enzymes potentially associated with sitagliptin.

  The Annals of pharmacotherapy 20100201

• [Pharmacovigilance update].

  Revue medicale suisse 20100120

• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  Journal of diabetes and its complications 20100101

• Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• Pancreatic duct replication is increased with obesity and type 2 diabetes in humans.

  Diabetologia 20100101

• Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.

  Journal of diabetes and its complications 20100101

• Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

  Diabetologia 20100101

• The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.

  Diabetes technology & therapeutics 20100101

• Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects.

  Pharmacology 20100101

• Do incretin-based therapies cause acute pancreatitis?

  Journal of diabetes science and technology 20100101

• Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.

  Vascular health and risk management 20100101

• Clinical approaches to preserve beta-cell function in diabetes.

  Advances in experimental medicine and biology 20100101

• [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

  Nederlands tijdschrift voor geneeskunde 20100101

• Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

  Endocrine journal 20100101

• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

  BMC endocrine disorders 20100101

• Dysglycemias in pregnancy: from diagnosis to treatment. Brazilian consensus statement.

  Diabetology & metabolic syndrome 20100101

• Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.

  Vascular health and risk management 20100101

• Rhinorrhea, cough and fatigue in patients taking sitagliptin.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20100101

• Forecasting drug utilization and expenditure in a metropolitan health region.

  BMC health services research 20100101

• Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

  Endocrine journal 20100101

• Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.

  PloS one 20100101

• Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.

  Therapeutics and clinical risk management 20100101

• Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

  BMC health services research 20100101

• Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society.

  Diabetology & metabolic syndrome 20100101

• Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.

  Cardiology in review 20100101

• The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20100101

• Sitagliptin intolerance.

  Allergologia et immunopathologia 20100101

• S28 peptidases: lessons from a seemingly 'dysfunctional' family of two.

  BMC biology 20100101

• A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

  Pharmacology 20100101

• Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis.

  PloS one 20100101

• Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).

  Mediators of inflammation 20100101

• Living Well with Diabetes: a randomized controlled trial of a telephone-delivered intervention for maintenance of weight loss, physical activity and glycaemic control in adults with type 2 diabetes.

  BMC public health 20100101

• Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review.

  PloS one 20100101

• Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

  Vascular health and risk management 20100101

• Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.

  Cardiovascular diabetology 20100101

• Exenatide once weekly: clinical outcomes and patient satisfaction.

  Patient preference and adherence 20100101

• Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

  Vascular health and risk management 20100101

• Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

  Clinical drug investigation 20100101

• Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20100101

• Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

  Cardiovascular diabetology 20100101

• Liraglutide in the management of type 2 diabetes.

  Drug design, development and therapy 20100101

• Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.

  BMC endocrine disorders 20100101

• The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session.

  Diabetology & metabolic syndrome 20100101

• [The incretin effect and type 2 diabetes].

  Revista medica del Instituto Mexicano del Seguro Social 20100101

• Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication.

  Patient preference and adherence 20100101

• Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Optimizing weight control in diabetes: antidiabetic drug selection.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Saxagliptin for type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

  Drug, healthcare and patient safety 20100101

• Use of sensors in the treatment and follow-up of patients with diabetes mellitus.

  Sensors (Basel, Switzerland) 20100101

• Pharmacological management of metabolic syndrome and its lipid complications.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101

• Exercise therapy in type 2 diabetes.

  Acta diabetologica 20091201

• Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.

  Diabetes 20091201

• Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

  Gastroenterology 20091201

• The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.

  Gastroenterology 20091201

• The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.

  Pharmacotherapy 20091201

• Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

  Cleveland Clinic journal of medicine 20091201

• Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

  European journal of pharmacology 20091125

• Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

  Diabetes, obesity & metabolism 20091101

• Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.

  Schizophrenia research 20091101

• Incretin-based therapies: viewpoints on the way to consensus.

  Diabetes care 20091101

• Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.

  Diabetes care 20091101

• Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

  Diabetes care 20091101

• Obesity in the elderly diabetic patient: is weight loss beneficial? No.

  Diabetes care 20091101

• Inventing and understanding catalytic, enantioselective reactions.

  Current opinion in drug discovery & development 20091101

• DPP-4 inhibitors in clinical practice.

  Postgraduate medicine 20091101

• A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20091101

• [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].

  MMW Fortschritte der Medizin 20091015

• [Combination antidiabetic therapy. Better control of blood glucose values].

  MMW Fortschritte der Medizin 20091015

• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

  Pharmacology & therapeutics 20091001

• Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

  Current medical research and opinion 20091001

• Pharmacotherapy of hyperglycemia.

  Expert opinion on pharmacotherapy 20091001

• Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.

  Journal of clinical pharmacology 20091001

• Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.

  Journal of managed care pharmacy : JMCP 20091001

• Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

  Clinical science (London, England : 1979) 20090928

• The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

  Diabetes care 20090901

• Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

  Diabetes care 20090901

• Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

  Diabetes 20090901

• Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.

  Journal of managed care pharmacy : JMCP 20090901

• Defining the importance of daily glycemic control and implications for type 2 diabetes management.

  Postgraduate medicine 20090901

• Direct asymmetric reductive amination.

  Journal of the American Chemical Society 20090819

• Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.

  European journal of medicinal chemistry 20090801

• Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090801

• Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.

  Journal of clinical pharmacology 20090801

• Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Dyshidrotic eczema: relevance to the immune response in situ.

  North American journal of medical sciences 20090801

• Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

  Diabetes care 20090701

• Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.

  Diabetes 20090701

• Highly efficient asymmetric synthesis of sitagliptin.

  Journal of the American Chemical Society 20090701

• Functional assessment of pancreatic beta-cell area in humans.

  Diabetes 20090701

• Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.

  Diabetic medicine : a journal of the British Diabetic Association 20090701

• Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

  European journal of internal medicine 20090701

• Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20090601

• Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

  The American journal of medicine 20090601

• CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.

  Prescrire international 20090601

• Sitagliptin: serious allergies. Risks greater than benefits.

  Prescrire international 20090601

• Initial therapy for type 2 diabetes. Examination of a combination approach.

  Advance for nurse practitioners 20090601

• [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].

  MMW Fortschritte der Medizin 20090507

• GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.

  Diabetes 20090501

• Impact of sitagliptin on markers of beta-cell function: a meta-analysis.

  The American journal of the medical sciences 20090501

• [The value of incretin based therapies].

  Deutsche medizinische Wochenschrift (1946) 20090501

• Incretin-based therapies for type 2 diabetes mellitus.

  Nature reviews. Endocrinology 20090501

• By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I be getting more aggressive in my treatment?

  Harvard health letter 20090501

• C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

  JAMA 20090415

• [Incretin related agents for treatment of diabetes mellitus].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410

• Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

  Journal of medicinal chemistry 20090409

• Effect of sitagliptin on the pharmacokinetics of simvastatin.

  Journal of clinical pharmacology 20090401

• Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20090401

• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

  Current medical research and opinion 20090401

• Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

  Diabetes 20090401

• Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry 20090315

• New treatments in type 2 diabetes: a focus on the incretin-based therapies.

  Clinical endocrinology 20090301

• Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

  Diabetes 20090301

• Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry 20090301

• Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

  Current medical research and opinion 20090301

• Diabetes treatment.

  Diabetes care 20090301

• Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.

  Pharmacotherapy 20090301

• Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090301

• DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.

  Advances in therapy 20090301

• Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.

  American family physician 20090301

• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

  Diabetic medicine : a journal of the British Diabetic Association 20090301

• Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Advances in therapy 20090301

• Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

  Advances in therapy 20090201

• Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

  Current drug metabolism 20090201

• Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.

  Prescrire international 20090201

• Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.

  Leukemia research 20090101

• Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

  Endocrinology 20090101

• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

  Diabetes care 20090101

• Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.

  Diabetes care 20090101

• Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

  Diabetes care 20090101

• Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

  Diabetes research and clinical practice 20090101

• Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

  Current drug targets 20090101

• Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.

  Postgraduate medicine 20090101

• Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.

  Postgraduate medicine 20090101

• Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

  Mymensingh medical journal : MMJ 20090101

• The therapeutic role of incretin mimetics and DPP-4 inhibitors.

  The Diabetes educator 20090101

• Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20090101

• Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

  BMC immunology 20090101

• Postprandial hyperglycemia as an etiological factor in vascular failure.

  Cardiovascular diabetology 20090101

• Challenging issues in molecular-targeted therapy.

  Therapeutics and clinical risk management 20090101

• Potential of liraglutide in the treatment of patients with type 2 diabetes.

  Vascular health and risk management 20090101

• I read about a new drug for diabetes called Januvia. Should I be interested in it?

  Heart advisor 20090101

• Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.

  PloS one 20090101

• Management of progressive type 2 diabetes: role of insulin therapy.

  Osteopathic medicine and primary care 20090101

• A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

  Cardiovascular diabetology 20090101

• Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.

  Current medicinal chemistry 20090101

• Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

  Therapeutics and clinical risk management 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  Journal of the American Pharmacists Association : JAPhA 20090101

• Efficacy and safety of incretin based therapies: clinical trial data.

  Journal of the American Pharmacists Association : JAPhA 20090101

• Diabetic nephropathy.

  Diabetology & metabolic syndrome 20090101

• Stem cell transplantation for type 1 diabetes mellitus.

  Diabetology & metabolic syndrome 20090101

• Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials.

  Diabetology & metabolic syndrome 20090101

• Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.

  Pharmacological reports : PR 20090101

• A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea: a case report.

  Cases journal 20090101

• Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

  Journal of diabetes science and technology 20090101

• Gliptins: a new class of oral antidiabetic agents.

  Indian journal of pharmaceutical sciences 20090101

• Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies.

  Journal of the American Society of Hypertension : JASH 20090101

• Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Alogliptin: a new addition to the class of DPP-4 inhibitors.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• DPP4 inhibitors for diabetes--what next?

  Biochemical pharmacology 20081215

• Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20081215

• Incretin-based therapies in type 2 diabetes: a review of clinical results.

  Diabetes research and clinical practice 20081215

• Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

  Diabetes, obesity & metabolism 20081201

• Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.

  Basic & clinical pharmacology & toxicology 20081201

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

  Diabetes care 20081201

• Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081201

• Management of type 2 diabetes in patients with heart failure.

  Current treatment options in cardiovascular medicine 20081201

• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

  Expert opinion on emerging drugs 20081201

• The role of incretins in glucose homeostasis and diabetes treatment.

  Pharmacological reviews 20081201

• Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.

  Acta bio-medica : Atenei Parmensis 20081201

• Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.

  Vascular health and risk management 20081201

• Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

  Vascular health and risk management 20081201

• Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

  Vascular health and risk management 20081201

• Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

  Cardiology clinics 20081101

• The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.

  Current diabetes reviews 20081101

• [Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].

  MMW Fortschritte der Medizin 20081030

• National trends in treatment of type 2 diabetes mellitus, 1994-2007.

  Archives of internal medicine 20081027

• Incretin-based therapies in type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20081001

• Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

  Current medical research and opinion 20081001

• Janumet: a combination product suitable for use in patients with Type 2 diabetes.

  Expert opinion on investigational drugs 20081001

• [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].

  Deutsche medizinische Wochenschrift (1946) 20081001

• [Sitagliptin].

  Revue de l'infirmiere 20081001

• Recent advances in the management of type 2 diabetes mellitus: a review.

  Postgraduate medical journal 20081001

• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

  Diabetic medicine : a journal of the British Diabetic Association 20081001

• Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.

  Prescrire international 20081001

• Natural products as inspiration for the development of asymmetric catalysis.

  Nature 20080918

• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20080901

• Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors.

  European journal of medicinal chemistry 20080901

• A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors.

  European journal of medicinal chemistry 20080801

• Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

  Diabetes care 20080801

• PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation.

  Diabetes 20080801

• Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.

  Diabetes 20080801

• Approaches to treatment of type 2 diabetes.

  Diabetes care 20080801

• Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

  Arquivos brasileiros de endocrinologia e metabologia 20080801

• RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20080801

• New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

  Vascular health and risk management 20080801

• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

  Vascular health and risk management 20080801

• [New drugs; exenatide and sitagliptin].

  Nederlands tijdschrift voor geneeskunde 20080726

• Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.

  Bioorganic & medicinal chemistry letters 20080715

• Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.

  British journal of clinical pharmacology 20080701

• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

  Diabetes, obesity & metabolism 20080701

• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

  Current opinion in clinical nutrition and metabolic care 20080701

• Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20080701

• Beyond insulin replacement: addressing the additional needs of the diabetes patient.

  Diabetes, obesity & metabolism 20080701

• Drugs for type 2 diabetes.

  Treatment guidelines from the Medical Letter 20080701

• From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.

  Current opinion in drug discovery & development 20080701

• Three new drugs for type 2 diabetes.

  Drug and therapeutics bulletin 20080701

• DPP4 inhibitors: a new approach in diabetes treatment.

  Advances in therapy 20080701

• Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

  Diabetes, obesity & metabolism 20080601

• Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.

  Hypertension (Dallas, Tex. : 1979) 20080601

• Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

  Expert opinion on investigational drugs 20080601

• New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

  Expert opinion on pharmacotherapy 20080601

• Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.

  The AAPS journal 20080601

• Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.

  Vascular health and risk management 20080601

• Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20080601

• A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.

  Endocrinology 20080501

• Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

  Diabetes 20080501

• Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.

  Journal of clinical pharmacology 20080501

• Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

  Naunyn-Schmiedeberg's archives of pharmacology 20080501

• Managed care perspective on three new agents for type 2 diabetes.

  Journal of managed care pharmacy : JMCP 20080501

• Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

  Frontiers in bioscience : a journal and virtual library 20080501

• Reducing global cardiovascular risk in patients with type 2 diabetes mellitus.

  The Journal of the American Osteopathic Association 20080501

• Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss.

  The Journal of the American Osteopathic Association 20080501

• Treating Hispanic patients for type 2 diabetes mellitus: special considerations.

  The Journal of the American Osteopathic Association 20080501

• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20080416

• [New drugs; exenatide and sitagliptin].

  Nederlands tijdschrift voor geneeskunde 20080412

• (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

  The Journal of pharmacology and experimental therapeutics 20080401

• New drug update: 2007.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401

• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20080401

• Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

  Vascular health and risk management 20080401

• [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].

  Lakartidningen 20080401

• What's new in clinical pharmacology and therapeutics.

  WMJ : official publication of the State Medical Society of Wisconsin 20080401

• Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080315

• Hypoglycaemia in Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20080301

• Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

  The AAPS journal 20080301

• [Sitagliptine (Januvia)].

  Journal de pharmacie de Belgique 20080301

• Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20080213

• Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

  Diabetes research and clinical practice 20080201

• Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction.

  Biomedical chromatography : BMC 20080201

• Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

  Current medical research and opinion 20080201

• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

  Current medical research and opinion 20080201

• Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.

  Prescrire international 20080201

• [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

  Revue medicale de Liege 20080201

• [Treatment with new preparations against type 2 diabetes not sufficiently documented].

  Lakartidningen 20080201

• Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.

  Diabetes & metabolism 20080201

• How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment.

  Bone marrow transplantation 20080101

• Dipeptidyl peptidase IV inhibitors and diabetes therapy.

  Frontiers in bioscience : a journal and virtual library 20080101

• Common crossroads in diabetes management.

  Osteopathic medicine and primary care 20080101

• Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.

  The Diabetes educator 20080101

• History and diagnostic significance of C-peptide.

  Experimental diabetes research 20080101

• Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

  Journal of managed care pharmacy : JMCP 20080101

• DPP-4 inhibitors. A new class of drugs for type 2 diabetes.

  Diabetes self-management 20080101

• Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

  Medscape journal of medicine 20080101

• Vaccination against GIP for the treatment of obesity.

  PloS one 20080101

• Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

  The review of diabetic studies : RDS 20080101

• New drugs for type 2 diabetes mellitus: what is their place in therapy?

  Drugs 20080101

• New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

  Drugs & aging 20080101

• Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

  BMC endocrine disorders 20080101

• What can we learn from drug marketing efficiency?

  BMJ (Clinical research ed.) 20080101

• New therapeutic approaches in type 2 diabetes.

  Acta clinica Belgica 20080101

• The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.

  Indian journal of pharmacology 20080101

• Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.

  Clinical medicine. Pathology 20080101

• Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.

  Bioorganic & medicinal chemistry letters 20071215

• Unlocking the potential of asymmetric hydrogenation at Merck.

  Accounts of chemical research 20071201

• DPP-4 inhibitors.

  Best practice & research. Clinical endocrinology & metabolism 20071201

• Inhaled insulin for controlling blood glucose in patients with diabetes.

  Vascular health and risk management 20071201

• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20071201

• Clinical management strategies for type 2 diabetes.

  JAAPA : official journal of the American Academy of Physician Assistants 20071201

• New treatments for type 2 diabetes--the DPP4 inhibitors.

  Primary care diabetes 20071201

• Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.

  Bioorganic & medicinal chemistry letters 20071101

• Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

  Drugs of today (Barcelona, Spain : 1998) 20071101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071101

• Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20071001

• [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].

  Vnitrni lekarstvi 20071001

• Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.

  Vascular health and risk management 20071001

• GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

  Current diabetes reports 20071001

• Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

  Biopharmaceutics & drug disposition 20070901

• Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

  Biopharmaceutics & drug disposition 20070901

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

  Diabetes, obesity & metabolism 20070901

• Using prandial insulin to achieve glycemic control in type 2 diabetes.

  The Journal of family practice 20070901

• Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

  Diabetes, obesity & metabolism 20070901

• [The incretin effect: a new therapeutic target in type 2 diabetes].

  Revue medicale de Bruxelles 20070901

• Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

  Diabetes care 20070801

• Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

  International journal of clinical practice. Supplement 20070801

• Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.

  International journal of clinical practice. Supplement 20070801

• Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

  Pharmacotherapy 20070801

• Type 2 diabetes drug boom: is newer better?

  The Johns Hopkins medical letter health after 50 20070801

• Type 2 diabetes: the end of clinical inertia.

  Southern medical journal 20070801

• [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].

  Medizinische Monatsschrift fur Pharmazeuten 20070801

• The burden of type 2 diabetes: strategies to prevent or delay onset.

  Vascular health and risk management 20070801

• Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors.

  Bioorganic & medicinal chemistry letters 20070715

• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  JAMA 20070711

• Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.

  Diabetes care 20070701

• [New concepts in the treatment of type 2 diabetes].

  Der Internist 20070701

• A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

  Current medical research and opinion 20070701

• New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.

  Heart advisor 20070701

• Management of comorbid diabetes and cancer.

  Oncology (Williston Park, N.Y.) 20070701

• Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

  Bioorganic & medicinal chemistry letters 20070615

• Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).

  Bioorganic & medicinal chemistry letters 20070615

• Sitagliptin/metformin (Janumet) for type 2 diabetes.

  The Medical letter on drugs and therapeutics 20070604

• Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

  Diabetes care 20070601

• Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

  Nature clinical practice. Endocrinology & metabolism 20070601

• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

  Current medical research and opinion 20070601

• Janumet.

  JAAPA : official journal of the American Academy of Physician Assistants 20070601

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20070501

• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

  Clinical pharmacology and therapeutics 20070501

• Treatment of type 2 diabetes mellitus and the incretin system.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20070501

• Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• Characterization of two cyclic metabolites of sitagliptin.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• beta-cell failure in diabetes and preservation by clinical treatment.

  Endocrine reviews 20070401

• Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

  Expert opinion on investigational drugs 20070401

• [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].

  Orvosi hetilap 20070401

• Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

  Current medical research and opinion 20070401

• [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].

  Revue medicale de Liege 20070401

• Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

  Vascular health and risk management 20070401

• Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

  Current opinion in endocrinology, diabetes, and obesity 20070401

• Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.

  Diabetes, obesity & metabolism 20070301

• Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20070301

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

  Diabetes, obesity & metabolism 20070301

• Diabetes drug update: how 4 new options stack up.

  The Journal of family practice 20070301

• Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.

  Journal of clinical pharmacology 20070201

• Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.

  Journal of clinical pharmacology 20070201

• Finding new treatments for diabetes--how many, how fast... how good?

  The New England journal of medicine 20070201

• Sitagliptin.

  Nature reviews. Drug discovery 20070201

• Incretins: a new treatment option for type 2 diabetes?

  The Netherlands journal of medicine 20070201

• (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry letters 20070101

• Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

  International journal of clinical practice 20070101

• Sitagliptin (Januvia) for type 2 diabetes.

  The Medical letter on drugs and therapeutics 20070101

• The physiology of incretin hormones and the basis for DPP-4 inhibitors.

  The Diabetes educator 20070101

• Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20070101

• Sitagliptin improved glycemic control and beta-cell function in type 2 diabetes.

  ACP journal club 20070101

• New drugs: sitagliptin phosphate, telbivudine, and panitumumab.

  Journal of the American Pharmacists Association : JAPhA 20070101

• New treatment for diabetes.

  FDA consumer 20070101

• Sitagliptin.

  Drugs 20070101

• Sitagliptin: a viewpoint by Mark S. Kipnes.

  Drugs 20070101

• Sitagliptin: a viewpoint by Itamar Raz.

  Drugs 20070101

• Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Current topics in medicinal chemistry 20070101

• [New class of oral antidiabetic drugs. Effective in combination with metformin].

  MMW Fortschritte der Medizin 20070101

• Sitagliptin: a novel drug for the treatment of type 2 diabetes.

  Cardiology in review 20070101

• Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.

  Journal of endocrinological investigation 20070101

• DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety.

  The review of diabetic studies : RDS 20070101

• First-in-class diabetes drug approved.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061201

• Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

  Diabetes care 20061201

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

  Diabetes care 20061201

• Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

  Diabetes & vascular disease research 20061201

• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  Lancet (London, England) 20061111

• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20061101

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

  Diabetologia 20061101

• DPP-4 inhibitors and their potential role in the management of type 2 diabetes.

  International journal of clinical practice 20061101

• Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

  Current medical research and opinion 20061001

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  Clinical therapeutics 20061001

• Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs.

  Experimental biology and medicine (Maywood, N.J.) 20060901

• Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.

  Geriatrics 20060901

• Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.

  Journal of clinical pharmacology 20060801

• American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20060801

• [DPP-4 inhibition raises incretin levels].

  Medizinische Monatsschrift fur Pharmazeuten 20060801

• Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

  Minerva endocrinologica 20060601

• Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

  Diabetes 20060601

• [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].

  Medizinische Monatsschrift fur Pharmazeuten 20060301

• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  Clinical therapeutics 20060101

• Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  The Annals of pharmacotherapy 20060101

• The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation.

  Pharmaceutical development and technology 20060101

• Basic Management of Diabetes Mellitus: Practical guidelines.

  The Libyan journal of medicine 20060101

• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.

  Clinical pharmacology and therapeutics 20051201

• American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.

  IDrugs : the investigational drugs journal 20050801

• MK-431 (Merck).

  Current opinion in investigational drugs (London, England : 2000) 20050401

• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20050113

• Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.

  Treatments in endocrinology 20050101

• New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

  The review of diabetic studies : RDS 20050101